Metoprolol kinetics and dose response in hypertensive patients

The kinetics and dose‐response characteristics of metoprolol were examined in a series of hypertensive patients. In 14 the elimination half‐life of metoprolol after single 100‐mg doses (4.1 ± 0.6 hr) was prolonged (p < 0.05) after 6 to 12 wk of therapy (5.6 ± 0.7 hr). In 5 patients receiving 100 mg twice daily evidence of nonlinear metoprolol kinetics emerged, because the area under the concentration‐time curve at steady state was 86.8% more (p < 0.02) than predicted from a single dose. Kinetic data from single doses of metoprolol appear to be a poor predictor of steady‐state kinetics. Single metoprolol dosage also induced a fall (p < 0.01) in blood pressure with pretreatment levels (163/108), reaching a minimum at 5 hr (133/89). During long‐term therapy incremental doses of metoprolol between 100 and 600 mg/day in 34 hypertensive patients resulted in a relatively horizontal dose‐response curve at doses above 200 mg/day.

[1]  Grant R. Wilkinson,et al.  A physiological approach to hepatic drug clearance , 1975 .

[2]  E. Frohlich,et al.  Immediate Hemodynamic Effects of Beta‐Adrenergic Blockade with Propranolol in Normotensive and Hypertensive Man , 1968, Circulation.

[3]  C. L. Jones,et al.  Rapid GLC determination of propranolol in human plasma samples. , 1977, Journal of pharmaceutical sciences.

[4]  D. Shand,et al.  Plasma binding and the affinity of propranolol for a beta receptor in man , 1976, Clinical pharmacology and therapeutics.

[5]  T. Walle,et al.  The predictable relationship between plasma levels and dose during chronic propranolol therapy , 1978, Clinical pharmacology and therapeutics.

[6]  C. von Bahr,et al.  Plasma levels and effects of metoprolol on blood pressure, adrenergic beta receptor blockade, and plasma renin activity in essential hypertension , 1976, Clinical pharmacology and therapeutics.

[7]  C. Dollery,et al.  Brain concentration of propranolol in relation to hypotensive effect in the rabbit with observations on brain propranolol levels in man. , 1975, The Journal of pharmacology and experimental therapeutics.

[8]  D. Shand,et al.  The hemodynamic effects of beta adrenergic blockade on the flow-dependent hepatic clearance of propranolol. , 1973, The Journal of pharmacology and experimental therapeutics.

[9]  J. Parker,et al.  Propranolol in the Treatment of Angina Pectoris: Comparison of Duration of Action in Acute and Sustained Oral Therapy , 1979, Circulation.

[10]  P. R. Reid,et al.  Lidocaine kinetics predicted by indocyanine green clearance. , 1978, The New England journal of medicine.

[11]  C. Regårdh,et al.  Comparative bioavailability and effect studies on metoprolol administered as ordinary and slow-release tablets in single and multiple doses. , 2009, Acta pharmacologica et toxicologica.

[12]  C. Regårdh,et al.  Plasma levels and effects of metoprolol on blood pressure and heart rate in hypertensive patients after an acute dose and between two doses during long‐term treatment , 1975, Clinical pharmacology and therapeutics.

[13]  D. Shand,et al.  Disposition of propranolol V. Drug accumulation and steady‐state concentrations during chronic oral administration in man , 1973, Clinical pharmacology and therapeutics.

[14]  C. Dollery,et al.  Atenolol in essential hypertension , 1976, Clinical pharmacology and therapeutics.